Dapirolizumab pegol (DZP) a novel drug wc inhibits CD40L signalling. In the PHOENYCS GO trial, pts on DZP+SOC achieved BICLA response at wk 48 vs. DZP+PBO -observed efficacy in SRI4, SLEDAI2K, LLDAS, BILAG -reduxn in steroid dose -well tolerated @RheumNow #ACR24 abL16 #ACRBest https://t.co/5tj2uwqeUz